GE’s mapping technology will be used to find prognostic biomarkers.
A team of scientists at GE Global Research, the technology development arm of GE Healthcare, has launched a study with Memorial Sloan-Kettering Cancer Center (MSKCC) to better understand the early stages of colon cancer.
“With colon cancer, we know that not all cases in the early stages of the disease are alike. Some are more aggressive than others,” notes John Burczak, chief scientist for molecular imaging at GE Global Research. “Through the promise of molecular analysis, we can identify those patients at higher risk and help ensure they receive the best possible treatment option.”
As part of the study, GE and MSKCC will collaborate to evaluate biomarkers for their prognostic value to segregate high- from low-risk early-stage colon cancers. They will work together to first identify cancer cases, acquire and process cancer tissues, collect treatment outcome information, biochemically and statistically analyze the molecular profiles for the cancer tissues, and relate the molecular profiles to treatment outcomes.
The research will leverage GE’s molecular pathology technology that can create a visual map of more than 25 proteins within a single tissue sample at the subcellular level. It applies imaging-analysis tools to collect and interpret the data.